4/A: MBX Biosciences Director Equity Grant Details

Steven L. Hoerter, a Director at MBX Biosciences, Inc., received an equity grant adjusted to comply with the company's compensation policy.

Summary

• Steven L. Hoerter, a Director of MBX Biosciences, Inc., was granted stock options on November 22, 2025.
• The grant was adjusted downwards to ensure the director's total annual equity compensation for 2025 does not exceed $1,000,000, based on grant date fair value per FASB ASC 718.
• The stock options have an exercise price of $27.08.
• The grant will vest in equal monthly installments over one year, starting from November 6, 2025, contingent upon continued service to the company.
• The filing also notes an amendment date of November 25, 2025, for a prior filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily detailing routine director compensation adjustments and equity grants rather than significant operational or financial news.

Positives

• Director Hoerter received an equity grant, aligning his interests with the company's performance.
• The equity grant is subject to a vesting schedule, encouraging long-term commitment.
• The company has a policy in place to cap director equity compensation, ensuring responsible governance.
• The grant is structured to vest over one year, providing a clear timeline for equity realization.

Negatives

• The grant was adjusted downwards, indicating a potential limitation on the intended compensation value.
• The specific number of shares or options granted is not explicitly stated, only the exercise price and total compensation cap.

Risks

• The vesting of the grant is contingent on continued service, meaning the director could forfeit unvested options if employment ceases.
• The downward adjustment of the grant value might impact the director's overall compensation package as originally planned.

Future Outlook

The equity grant is subject to a one-year vesting period starting November 6, 2025, and expiring November 21, 2035. The total annual equity compensation for non-employee directors in 2025 is capped at $1,000,000 based on grant date fair value.

Management Comments

• The grant was adjusted downward to comply with the Non-Employee Director Compensation Policy, capping annual equity compensation at $1,000,000.
• The grant will vest in equal monthly installments over one year, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology sector to align executive and director interests with shareholder value. The adjustment mechanism described suggests a structured approach to compensation governance, which is increasingly scrutinized by investors.

Corporate Governance

Related Party Transactions

• Grant of stock options to Director Steven L. Hoerter, subject to the company's Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The compensation policy ensures that director equity awards are managed within a defined limit, potentially preserving shareholder value.
• Directors: Steven L. Hoerter will receive equity compensation that vests over time, contingent on continued service.
• Employees: Indirect impact through the company's governance practices and compensation structures.

Next Steps

• The equity grant will vest monthly over one year from November 6, 2025.
• The director's continued service is required for vesting.

Key Dates

Keywords

MBX Biosciences, Form 4, Director Compensation, Equity Grant, Stock Options, Beneficial Ownership, Vesting Schedule, SEC Filing